Heparin calcium is calcium salt form of heparin. Heparin calcium is a negatively charged linear polysaccharide that belongs to the glycosaminoglycan family. Нeparin is an anticoagulant which is indicated for the prevention and treatment of thrombotic events such as pulmonary embolism, deep vein thrombosis and atrial fibrillation. As a glycosaminoglycan anticoagulant, heparin calcium binds to antithrombin III to form a heparin-antithrombin III complex. Heparin is also used to prevent excess coagulation during cardiac surgery, dialysis, and others. Heparin can be administered by intravenous or subcutaneous route. Unfractionated heparin and low molecular weight heparin are the two forms of calcium heparin. Subcutaneous heparin is administred to prevent thromboembolism and the administration of intravenous heparin is used for therapeutic anticoagulation. Bleeding, thrombocytopenia, injection site reactions, and other adverse effects are seen with chronic heparin administration. Bleeding is a major complication associated with heparin use. In long term use, unfractionated heparin has a higher risk of osteoporosis. Unfractionated heparin is more specific than low molecular weight heparin for thrombin and the effects of unfractionated heparin can typically be reversed by using protamine sulfate.
Market Dynamics
Increasing adoption of inorganic strategies such as launch of campaign, in order to raise awareness is expected to drive the global heparin calcium market growth over the forecast period. For instance, in November 2020, The Bristol Myers Squibb–Pfizer Alliance, announced that they had launched the ‘No Time to Wait’ awareness campaign, to raise awareness of the symptoms of deep vein thrombosis. This campaign helps people to find additional information about deep vein thrombosis.
Key features of the study:
- This report provides an in-depth analysis of the global heparin calcium market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global heparin calcium market based on the following parameters–company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Sanofi, Pfizer Inc., Dongying Tiandong Pharmaceutical Co., Ltd., PANPHARMA S.A., Merck KGaA, Teva Pharmaceutical Industries Ltd., SMITHFIELD BIOSCIENCE, Afine Chemicals Limited, Yino Pharma Limited, Shandong Sheelian Pharmaceutical Co., Ltd., Aspen Holdings, Opocrin S.p.A.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global heparin calcium market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global heparin calcium market
Detailed Segmentation:
- Global Heparin Calcium Market, By Type:
- Unfractionated Heparin
- Low Molecular Weight Heparin
- Global Heparin Calcium Market, By Route of Administration:
- Global Heparin Calcium Market, By Application:
- Kidney Dialysis
- Atrial Fibrillation
- Deep Vein Thrombosis
- Pulmonary Embolism
- Others (Cardiac Surgery, etc.)
- Global Heparin Calcium Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Heparin Calcium Market, By Region:
- North America
- Latin America
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Country/Regions
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Sanofi*
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Pfizer Inc.
- Dongying Tiandong Pharmaceutical Co., Ltd.
- PANPHARMA S.A.
- Merck KGaA
- Teva Pharmaceutical Industries Ltd.
- SMITHFIELD BIOSCIENCE
- Afine Chemicals Limited
- Yino Pharma Limited
- Shandong Sheelian Pharmaceutical Co., Ltd.
- Aspen Holdings
- Opocrin S.p.A.
“*” marked represents similar segmentation in other categories in the respective section.
